ADAURA2 is a phase 3, randomized, double-blind, placebo-controlled study evaluating adjuvant osimertinib vs. placebo in patients with stage IA2-IA3 EGFR-mutant NSCLC after surgical resection, stratified for pathologic risk of disease recurrence (high vs. low), EGFR mutation type (exon 19 deletion vs. L858R), and race (Chinese Asian vs. non-Chinese Asian vs. non-Asian). This evidence concerns the gene EGFR and non-small cell lung carcinoma.